Thus, identification of new molecular targets such as PURPL described in this study, and subsequent characterization of the cellular mechanisms underlying chemoresistance are urgently needed to develop new therapeutic strategies for effectively reversing chemoresistance in HCC. The gene discussed is PURPL; the disease is hepatocellular carcinoma.